| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | Zydelig (EU) | |
| 3 | Generic Name | idelalisib | |
| 4 | Indication | 2L CLL, 1L CLL 17p/TP53 mutations, 3L FL | |
| 5 | Economics | ||
| 6 | Regulatory | MAA under file and CHMP recommended approval on 7/25/14. | |
| 7 | Administration | 150mg film-coated tablets | |
| 8 | Mechanism | ||
| 9 | History | ||
| 10 | Clinical Trials | ||
| 11 | Phase III "Study 116" Zydelig + Rituxan in n=x 2L CLL. NEJM 2014. | ||
| 12 | |||
| 13 | Phase II "Study 101-09" in n=x 3L iNHL. NEJM 2014. |